Journal Article Summary
The article investigates the effectiveness of dual antithrombotic therapy (DAT) compared to triple antithrombotic therapy (TAT) in patients who are on oral anticoagulants (OAC) and have undergone percutaneous coronary intervention (PCI). This topic is important because recent European guidelines have shifted towards recommending DAT, which includes a P2Y12 inhibitor and OAC without aspirin. Understanding the outcomes of these therapies can help improve patient safety and treatment strategies for those at risk of thrombotic events.
In the study, researchers analyzed data from 1,075 patients who received either DAT or TAT after PCI between 2014 and 2021. Most participants were on OAC due to atrial fibrillation, and they were divided into two groups: 60.9% received DAT while 39.1% were on TAT. The findings revealed that DAT was linked to a significantly lower risk of clinically relevant bleeding compared to TAT (16.8% vs 23.4%), while the rates of major adverse cardiac and cerebrovascular events were similar between the two groups.
However, the study has limitations, including its observational nature and the potential for selection bias, which may affect the generalizability of the results. Patients should discuss their individual risks and treatment options with their healthcare providers, especially considering the balance between the benefits of preventing thrombotic events and the risks of bleeding. This conversation is crucial for making informed decisions about antithrombotic therapy after PCI.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Bor Willem Lambertus, de Veer Anne Johanna Wilhelmina, Olie Renske H., Rikken Sem A.O.F., Chan Pin Yin Dean R.P.P., Herrman Jean-Paul R., Vrolix Mathias, Meuwissen Martijn, et al.. Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study. EuroIntervention 2022. DOI: 10.4244/EIJ-D-21-00703. PMID: 35370126. PMCID: PMC9980408.
Featured Pill Pals Product
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs --- Over The Counter
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over — Generic For Bayer Low Dose — Time Cap Labs — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
